Bright, according to Stat News, is moving into a smaller role at the National Institutes of Health. Gary Disbrow, Bright's former deputy, will serve as the acting director of the office, an HHS spokesperson said.



Bright has also worked for the Atlanta-based Centers for Disease Control and Prevention and as an adviser to the World Health Organization.

BARDA invests in drugs, devices and other technologies that help address infectious disease outbreaks and has been at the center of the federal government’s coronavirus pandemic response.

US records lowest coronavirus-related deaths in 2 weeks

Congress more than tripled BARDA’s budget in the most recent coronavirus stimulus package. The office has partnered with Johnson & Johnson and Moderna Therapeutics, both of which are developing potential COVID-19 treatments.

Johnson & Johnson, while slashing its 2020 sales forecast by billions of dollars and cutting its profit expectations, is aiming to have its single-dose vaccine candidate available for broad use early in 2021.

FDA clears first COVID-19 saliva test

It also is testing two backup vaccine candidates. The company has a long track record on vaccines, developing ones for HIV, Ebola and the Zika virus during the last decade.

BARDA’s director reports directly to the HHS assistant secretary for preparedness and response.

Rich Barak of The Atlanta Journal-Constitution contributed to this report.